
 
 
 
 
 
 
 
 
   
 1. one kind with
           18 f or
           19 the method of F tagged molecule, described method comprise by
           18 f or
           19 the mixture of F and IIIA race metal is connected to chelating moiety, and wherein described chelating moiety is conjugated to described molecule or described chelating moiety is connected to described molecule subsequently, described chelating moiety is NODA-MPAA or NODA-MPAEM:
         
 
 
 
   。
         
 
     
 
   
 
 2. method according to claim 1, is wherein conjugated to described molecule by described chelating moiety. 
 
     
 
   
 
 3. method according to claim 1, is wherein connected to described molecule subsequently by described chelating moiety and described method also comprises described chelating moiety is connected to described molecule. 
 
     
 
   
 
 4. method according to claim 1, wherein said molecule is protein or peptide. 
 
     
 
   
 
 5. method according to claim 1, wherein said molecule is the targeted molecular being selected from antibody, antibody fusion protein and antigen binding antibody fragment. 
 
     
 
   
 
 6. method according to claim 1, wherein said molecule is the targeted molecular being selected from monoclonal antibody, bi-specific antibody and multi-specificity antibody. 
 
     
 
   
   
 
 7. the method described in claim 5 or 6, being wherein conjugated to by described chelating moiety can target construct. 
 
     
 
   
 
 8. method according to claim 1, wherein said IIIA race metal is selected from aluminium, gallium, indium, lutetium and thallium. 
 
     
 
   
 
 9. method according to claim 1, wherein said IIIA race metal is aluminium. 
 
     
 
   
 
 10. method according to claim 7, wherein saidly can be selected from SEQ ID NO:5, SEQ ID NO:4, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:29, SEQ ID NO:32, SEQ ID NO:30, SEQ ID NO:35, SEQ ID NO:36 and SEQ ID NO:37 by target construct. 
 
     
 
   
 
 11. methods according to claim 1, wherein said
           18 f or
           19 f tagged molecule start by
           18 f or
           19 produced in 30 minutes after the mixture of F and IIIA race metal is connected to chelating moiety.
         
 
     
 
   
 
 12. methods according to claim 1, described in wherein inciting somebody to action
           18 f or
           19 f mixture is connected to described chelating moiety in water-bearing media.
         
 
     
 
   
 
 13. methods according to claim 12, wherein add organic solvent to incite somebody to action in described medium
           18 f or
           19 f mixture is connected to chelating moiety.
         
 
     
 
   
 
 14. methods according to claim 1, described in wherein inciting somebody to action by microwave radiation
           18 f or
           19 f mixture is connected to described chelating moiety.
         
 
     
 
   
 
 15. methods according to claim 1, described in wherein inciting somebody to action by heating
           18 f or
           19 f mixture is connected to described chelating moiety.
         
 
     
 
   
   
 
 Method described in 16. claims 5 or 6, wherein prepares described targeted molecular by stop and lock-in techniques. 
 
     
 
   
 
 17. methods according to claim 3, are wherein connected to described molecule by click chemistry reaction by chelating moiety. 
 
     
 
   
 
 18. methods according to claim 3, are wherein connected to described molecule by maleimide-sulfydryl reaction by described chelating moiety. 
 
     
 
   
 
 19. methods according to claim 7, wherein radiolabeled can the yield of target construct be at least 85%. 
 
     
 
   
 
 20. methods according to claim 7, wherein said can the specific activity of target construct be at least 115 GBq/ μm ol. 
 
     
 
   
 
 21. methods according to claim 7, wherein before radio-labeling described in freeze-drying can target construct for storage. 
 
     
 
   
 
 22. methods according to claim 21, wherein by described can the freeze-drying in the weighting agent being selected from sorbyl alcohol, N.F,USP MANNITOL and trehalose of target construct. 
 
     
 
   
 
 23. methods according to claim 1, are wherein connected to described chelating moiety under the pH of 3.8 to 4.5
           18 f or
           19 f mixture.
         
 
     
 24. 1 kinds can target construct, its comprise be connected to metal-
           18 f, metal-
           19 f or
           68 the chelating moiety of Ga, wherein said chelating moiety is NODA-MPAA or NODA-MPAEM:
         
 
 
 
   。
         
 
     
 
   
 
 25. according to claim 24 can target construct, wherein saidly can be selected from SEQ ID NO:5, SEQ ID NO:4, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:29, SEQ ID NO:32, SEQ ID NO:30, SEQ ID NO:35, SEQ ID NO:36 and SEQ ID NO:37 by target construct. 
 
     
 26. 1 kinds of compositions, it comprises NODA-MPAA or NODA-MPAEM: 
 
 
 
   。
         
 
     
 
   
 
 The composition of 27. claims 26, is wherein conjugated to molecule by described NODA-MPAA or NODA-MPAEM. 
 
     
 
   
 
 The composition of 28. claims 26, wherein by described NODA-MPAA or NODA-MPAEM and metal
           18 f compound.
         
 
     
 
   
 
 The composition of 29. claims 26, wherein by described NODA-MPAA or NODA-MPAEM and Al-
           18 f compound.
         
 
     
 
   
 
 The composition of 30. claims 26, wherein by described NODA-MPAA or NODA-MPAEM and
           68 ga compound.
         
 
     
 31. 1 kinds of utilizations
           18 f or
           19 the method of F tagged molecule, it comprises;
         
 A) IIIA race metal is connected to chelating moiety in water-bearing media to form metal-chelating moiety mixture, wherein described chelating moiety is conjugated to described molecule or subsequently described chelating moiety is connected to described molecule; With 
 B) will
           18 f or
           19 f is added into metal-chelating moiety mixture, wherein said
           18 f or
           19 f in conjunction with described metal,
         
 Wherein said chelating moiety is NODA-MPAA or NODA-MPAEM: 
 
 
 
   。
         
 
     
 32. chelating moieties for the preparation of with
           18 f or
           19 purposes in the diagnostic reagent of F tagged molecule, wherein said mark comprises: will
           18 f or
           19 the mixture of F and IIIA race metal is connected to chelating moiety, wherein described chelating moiety is conjugated to described molecule or described chelating moiety is connected to described molecule subsequently;
         
 Described targeted molecular is used to experimenter; 
 Allow the sufficient time so that described targeted molecular is in conjunction with target antigen; With 
 Give subsequently described experimenter use described can target construct, wherein said can target construct in conjunction with described targeted molecular; 
 Wherein said molecule is the targeted molecular being selected from antibody, antibody fusion protein and antigen binding antibody fragment; With 
 Wherein being conjugated to by described chelating moiety can target construct, and described chelating moiety is NODA-MPAA or NODA-MPAEM: 
 
 
 
   。
         
 
     
 
   
 
 33. purposes according to claim 32, wherein said molecule is the targeted molecular being selected from monoclonal antibody, bi-specific antibody and multi-specificity antibody. 
 
     
 
   
 
 34. purposes according to claim 32, it also comprises use PET scanning with described in experimenter described in imaging
           18 the distribution of F tagged molecule.
         
 
     
 
   
 
 35. purposes according to claim 32, wherein said targeted molecular passes through in conjunction with diseased cells or pathogenic agent and comprising
           18 the PET imaging of F tagged molecule or
           19 the NMR imaging of F tagged molecule detects, diagnose or the existence of disease described in imaging or pathogenic agent.
         
 
     
 
   
 
 36. purposes according to claim 35, wherein said disease selected from cancer, cardiovascular disorder, communicable disease, inflammatory diseases, autoimmune disease, immune dysfunction disease, graft versus host disease (GVH disease), organ-graft refection and sacred disease. 
 
     
 
   
 
 37. purposes according to claim 36, wherein said targeted molecular conjugated antigen, described antigen is selected from carbonic anhydrase IX, CCCL19, CCCL21, CSAp, CD1, CD1a, CD2, CD3, CD4, CD5, CD8, CD11A, CD14, CD15, CD16, CD18, CD19, IGF-1R, CD20, CD21, CD22, CD23, CD25, CD29, CD30, CD32b, CD33, CD37, CD38, CD40, CD40L, CD45, CD46, CD52, CD54, CD55, CD59, CD64, CD66a-e, CD67, CD70, CD74, CD79a, CD80, CD83, CD95, CD126, CD133, CD138, CD147, CD154, CXCR4, CXCR7, CXCL12, HIF-1 α, AFP, PSMA, CEACAM5, CEACAM-6, c-met, B7, the ED-B of fibronectin, factor H, FHL-1, Flt-3, folacin receptor, GROB, HMGB-1, hypoxia inducible factor (HIF), HM1.24, insulin-like growth factor-i (ILGF-1), IFN-γ, IFN-α, IFN-β, IL-2, IL-4R, IL-6R, IL-13R, IL-15R, IL-17R, IL-18R, IL-6, IL-8, IL-12, IL-15, IL-17, IL-18, IL-25, IP-10, MAGE, mCRP, MCP-1, MIP-1A, MIP-1B, MIF, MUC1, MUC2, MUC3, MUC4, MUC5, NCA-95, NCA-90, Ia, HM1.24, EGP-1, EGP-2, HLA-DR, tenascin, Le (y), RANTES, T101, TAC, Tn antigen, Thomson-Friedenreich antigen, tumor necrosis antigens, TNF-α, TRAIL acceptor (R1 and R2), VEGFR, EGFR, PIGF, complement factor C_3, C3a, C3b, C5a, C5 and oncoprotein. 
 
     
 
   
 
 38. purposes according to claim 36, wherein said communicable disease is relevant to pathogenic agent, and described pathogenic agent is selected from fungi, virus, parasite and bacterium. 
 
     
 
   
 
 39. purposes according to claim 36, wherein said communicable disease is relevant to pathogenic agent, and described pathogenic agent is selected from human immunodeficiency virus (HIV), simplexvirus, cytomegalovirus, rabies virus, influenza virus, hepatitis B virus, Sendai virus, feline leukaemia virus, reovirus, poliovirus, the tiny sample virus of human serum, simian virus 40, respiratory syncytial virus, mouse mammary tumour virus, varicella zoster virus, dengue virus, rubella virus, Measles virus, adenovirus, human T-cell leukemia virus, Epstein-Barr virus, murine leukemia virus, mumps virus, vesicular stomatitis virus, sindbis alphavirus, lymphocytic choriomeningitis virus, verrucosis poison and blue tongue rims, streptococcus agalactiae, legionella pneumophilia, streptococcus pyogenes, intestinal bacteria, Diplococcus gonorrhoeae, Neisseria meningitidis, Pn, H influenzae type B, Treponoma palladium, lyme disease spirochete, Pseudomonas aeruginosa, Mycobacterium leprae, Brucella abortus, mycobacterium tuberculosis and clostridium tetani. 
 
     
 
   
 
 40. purposes according to claim 36, wherein said autoimmune disease is selected from immune-mediated thrombocytopenia, acute idiopathic thrombocytopenic purpura, chronic idiopathic thrombocytopenic purpura, dermatomyositis, siogren's syndrome, multiple sclerosis, SC, myasthenia gravis, systemic lupus erythematous, lupus nephritis, rheumatic fever, polyglandular syndrome, bullous pemphigoid, diabetes, purpura,Henoch-Schonlein, post-streptococcal infection nephritis, erythema nodosum, aortic arch syndrome, Addison disease, rheumatoid arthritis, osteitis tuberculosa cystica, ulcerative colitis, erythema multiforme, IgA nephropathy, polyarteritis nodosa, ankylosing spondylitis, Goodpasture's syndrome, thromboangiitis obliterans, primary biliary cirrhosis, struma lymphomatosa, thyrotoxicosis, scleroderma, chronic active hepatitis, polymyositis/dermatomyositis, polychondritis, pemphigus vulgaris, Wei Genashi granuloma, membranous nephropathy, amyotrophic lateral sclerosis, myelophthisis, giant cell arteritis/polymyalgia, pernicious anemia, rapidly progressive glomerulonephritis and FA. 
 
     
 
   
 
 41. purposes according to claim 35, wherein said targeted molecular is the antibody being selected from anti-IGF-1R antibody, anti-carcinoma of the pancreas Saliva Orthana antibody, anti-CD 20 antibodies, anti-CD19 antibody, anti-AFP antibody, anti-CD74 antibody, anti-CD22 antibody, anti-CSAp antibody, anti-HLA-DR antibody, anti-CEACAM5 antibody, anti-CEACAM6 antibody, anti-EGP-1 antibody and anti-CEACAM6 antibody. 
 
   
 
 
 
 
 
 
 
 
